---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-345807"
form_type: "8-K"
ticker: "AVLN"
cik: "0001540171"
company_name: "Avalyn Pharma Inc."
filed_at: "2026-08-12T12:06:35+00:00"
generated_at: "2026-08-12T12:10:24.322086+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Avalyn reports Q2 net loss $28.9M; completes MIST enrollment with 398 patients

## Summary
- Net loss $28.9M in Q2 2026 vs $20.2M in Q2 2025; R&D $24.7M, G&A $6.6M.
- Cash, equivalents, marketable securities $413.5M at June 30, 2026; runway into 2029.
- MIST Phase 2b fully enrolled with 398 patients (target 375); topline data expected H2 2027.
- AURA Phase 2 enrollment on track (160 patients); topline late 2027; AP03 Phase 1 to start by end 2026.
- May 2026 IPO raised ~$316.6M in net proceeds.

## SEC filing metadata
- accession: 0001193125-26-345807
- form_type: 8-K
- ticker: AVLN
- cik: 0001540171
- company_name: Avalyn Pharma Inc.
- filed_at: 2026-08-12T12:06:35+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540171/000119312526345807/0001193125-26-345807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540171/000119312526345807/ck0001540171-20260812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-345807
- JSON: https://secwatch.observer/filing/0001193125-26-345807.json
- Plain text: https://secwatch.observer/filing/0001193125-26-345807.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.